Backgrounds and Aims: The effect of cigarette smoking [CS] is ambivalent since smoking improves ulcerative colitis [UC] while it worsens Crohn's disease [CD]. Although this clinical relationship between inflammatory bowel disease [IBD] and tobacco is well established, only a few experimental works have investigated the effect of smoking on the colonic barrier homeostasis focusing on xenobiotic detoxification genes. Results: Of the 244 detoxification genes investigated, 65 were dysregulated in UC patients in comparison with healthy controls or CD patients. The expression of ≥ 45/65 genes was inversed by CS in biopsies of smoking UC patients in remission and in colonic explants of UC patients exposed to cigarette smoke extract. We devised a network-based data analysis approach for differentially assessing changes in genetic interactions, allowing identification of unexpected regulatory detoxification genes that may play a major role in the beneficial effect of smoking on UC. Conclusions: Non-inflamed colonic mucosa in UC is characterised by a specifically altered detoxification gene network, which is partially restored by tobacco. These mucosal signatures could be useful for developing new therapeutic strategies and biomarkers of drug response in UC.
Introduction
The exact aetiology of ulcerative colitis [UC] remains poorly understood. More than 130 genetic risk loci involved in biological pathways including immune response, maintenance of intestinal barrier function, and endoplasmic reticulum stress, have been identified so far. 1, 2 However, the concordance rate in monozygotic versus disygotic twins is 16% in control versus 4% in UC twins, 3, 4 suggesting a role of environmental factors in the pathological process of UC. Western lifestyle seems strongly associated with the high incidence of UC [24. 3/100 000 person-years in Europe and 6.3/100 000 person-years in Asia 5 ] and the rising incidence of inflammatory bowel disease [IBD] in Western countries has generally pre-dated that in developing countries. The significant impact of industrialisation [exposure to pollutants, pesticides, etc.] on the occurrence of UC indicates that changes in the toxic environment are the major causes of this evolution and suggests that impaired ability to detoxify environmental toxicants could promote UC.
The most indisputable example of the influence of the environment on IBD is cigarette smoking [CS] which has a striking opposite effect on UC and Crohn's disease [CD] . 6, 7 Although cigarette use is an important risk factor for CD, UC patients are frequently non-smokers and smoking cessation increases the risk of developing UC. However, the protective molecular mechanisms of CS on UC remain obscure. Although some studies have demonstrated that nicotine has an antiinflammatory function in UC, 8, 9 the findings from clinical studies, systematic reviews, and meta-analyses do not support the efficacy of nicotine preparations on the induction of disease remission. 10 Cigarette smoke contains numerous toxic compounds. The human xenobiotic-metabolising enzyme [XME] machinery is a major protective factor against environmental exposure 11 and can be induced by various exogenous and endogenous agents. Although the liver is the major organ for detoxification, colonic epithelial cells have a similar capacity to detoxify luminal and blood compounds. 12, 13 The colon is exposed to various foreign chemicals [called xenobiotics], including drugs, food additives, pollutants, etc. Therefore, the proper functioning of the detoxification system is critical for protection of intestinal barrier. Xenobiotic metabolism and excretion are mediated by a large number of phase I, phase II, and phase III XMEs.
14 Phases I and II XMEs can synergistically transform lipophilic xenobiotics into hydrophilic metabolites to facilitate the excretion of toxicants. Phase I XMEs encompass a family of 50-100 enzymes [referred to as cytochrome P450, CYP] which mainly catalyse the oxidative metabolism of unwanted chemical compounds. Numerous CYP enzymes are expressed in the human normal colon and rectum. 12, 15 Phase II reactions include the sulphation, glucuronidation, acetylation, methylation, and glutathione conjugation of xenobiotic derivatives which have undergone phase I XMEs. Phase III XMEs or transporters mainly consist in adenosine triphosphate [ 14 Evidence suggests that colonic epithelial cells become unable to detoxify toxic metabolites in cases of colitis. [16] [17] [18] The activation of the xenobiotic metabolic pathways improves dextran sodium sulphate [DSS]-induced colitis 19 and modulates the activity of immune and non-immune cells in the gut. 20 A few data from animal models 20, 21 together with studies in IBD patients 13, 18, 22, 23 suggest that detoxification enzyme depletion could be involved in UC initiation and/or progression. However, the information provided by these studies is limited and most often concerns a small number of XME genes. Furthermore, unlike the well-established relationship between IBD and CS, no experimental works have explored the effect of CS on the detoxification gene network in humans.
Using a combined approach integrating detoxification gene mRNA expression levels and network-based data analysis, our findings support an impaired detoxification capacity of the non-affected colonic mucosa of UC patients which was not found in healthy controls or patients with colonic CD. We developed a new method to infer a gene regulatory network from gene expression data, by integrating existing knowledge into the under-determined inverse network inference problem. Through this method, we identified new unexpected genes and gene interactions which could be responsible for the dysregulation of the detoxification system and the environmental susceptibility of UC.
Methods

Patients and biopsies
Human ascending colon biopsies were obtained from the IBD Gastroenterology Unit, Beaujon Hospital. were selected and included in this study. Colonic CD patients were recruited to assess whether dysregulated detoxification gene expression profile was a general hallmark of IBD or a more specific feature of UC. Patients were consecutively recruited from January 2010 to October 2013. All patients were diagnosed based on classical clinical features as well as radiological, endoscopic, and histological findings. All biopsies were taken from the non-inflamed right colon to avoid variability in detoxification enzyme expression along the colon, and analysed by an expert gastrointestinal [GI] pathologist [DCH] . Unaffected areas were defined as mucosa regions without any macroscopic/endoscopic or histological signs of inflammation, as previously reported. 24 To preserve tissue transcriptional profiles, biopsy specimens were immediately kept at -80°C until RNA extraction. 
Isolation of total mRNA and reverse transcription
Preparation of cigarette smoke extract and treatment of biopsies
Water-soluble extracts of cigarette smoke were generated by bubbling smoke from research-grade standard filter cigarettes in serum-free culture medium using a vacuum pump smoking machine [Heinrich Borgwaldt, Hambourg, Germany] settled with standard puff parameters [35 ml volume, 2 s duration, 60 s frequency]. Under these conditions each cigarette is consumed after 10 puffs, approximately mimicking the human smoking pattern. 25 The aqueous smoke extract from one cigarette corresponded to 10 puffs [350 ml] bubbled in 5 ml culture medium. The final dilutions of cigarette smoke extract in culture media were expressed as puffs/ml. Non-affected colon biopsies obtained from non-smoking UC patients were cultured for 2 h in the presence or absence of cigarette smoke extract at a final concentration of 1.6% [0.36 puff/ml], rinsed twice with phosphate buffered saline [PBS] , and then immediately kept at -80°C until RNA extraction. This concentration was chosen because viability studies demonstrated lack of non-specific toxicity as determined by lactate dehydrogenase [LDH] release [data not shown]. Though most of the effects presented here were obtained with Kentucky 2R4F cigarettes, similar effects were obtained using filter commercially available cigarettes.
Immunohistochemistry
Immunohistological methods were used on serial 4-µm paraffinembedded sections from control and unaffected UC mucosa. All sections were deparaffinised in xylene, rehydrated incubated in 3% hydrogen peroxide, and heated for 10 min in 10 mM citrate buffer [pH 6.2]. Sections were incubated in a blocking buffer for 1 h at room temperature using the Vectastain universal elite ABC kit [Clinisciences, Nanterre, France], and then incubated with anti-ARNT, anti-ABCA1, anti-HIF3A, or anti-CYP1B1 antibodies overnight at 4°C [all primary antibodies were purchased from Abcam, UK]. Secondary biotinylated anti-mouse or anti-rabbit were detected using the Vectastain universal elite ABC kit.
Principal component analysis
Principal components [PC] were computed after a logarithmic transformation of the expression levels, using the MATLAB function princomp. The first two PCs, which accounted for 85% of the total variance, are shown in Supplementary Figure 1 , available as Supplementary data at ECCO-JCC online. For each of the 39 patients, the projections of individual expression vectors on the first two PCs were computed. 
Multiple correspondence analysis
Statistical analysis
Statistical analysis was performed using Prism Version 5.0 [GraphPad software, Inc., San Diego, CA]. The Mann-Whitney test was used to determine the intergroup statistical significance. Values were considered statistically significant when p < 0.05. Results are expressed as mean ± standard error of the mean [SEM] . Clustering was performed using dChip software.
Network-based analysis
Integrative network inference
Given a gene expression vector x whose components x i represent the expression level of the gene i, we aimed at inferring a possible genetic interaction network consistent with the expression x. This inverse problem has received a lot of interest in the past few years, and we refer to reference 8 for a recent report on this topic. Given the large number of unknown parameters [n 2 interaction pairs] and the low number of data points (n expression levels], our approach aimed at integrating existing knowledge on genetic interactions to add constraints [see Results] and reduce the under-determination of the problem. We direct the reader to Supplementary materials [available as Supplementary data at ECCO-JCC online] for a detailed full description of the algorithm.
Comparative analysis
A detailed description of the optimisation algorithm used to solve this constrained basis pursuit problem as well as metric and classification methods are presented in Supplementary materials.
Results
Detoxification gene expression profiles are impaired in the non-inflamed colonic mucosa of UC patients
The expression of 244 genes encoding for detoxification enzymes known to be expressed in the human colon 12 was quantified by qRT-PCR in non-inflamed colonic biopsies taken from the right colon of UC patients [n = 19] been reported to be dysregulated in both IBD patients and mouse colitis models. 20, 23, [26] [27] [28] A hierarchical cluster analysis identified two distinct clusters based on the similarity of the 65 gene expression profiles, clearly distinguishing UC patients from healthy subjects [P = 0.009] [ Figure 1A ]. The detoxification gene expression profile was then analysed in the non-inflamed colonic mucosa of 18 CD patients. As shown in Figure 1B , the gene expression profiles in CD patients and healthy controls were quite similar, with only 15/65 similar gene expression profiles compared with UC patients [ Table 1 ]. These data demonstrated a specific dysregulated detoxification gene expression in the non-inflamed colonic mucosa of UC patients.
To confirm these mRNA differences at the protein level, four down-regulated genes were analysed by immunohistochemistry on an independent set of biopsies. The tested genes included the aryl hydrocarbon receptor nuclear translocator 
Effect of cigarette smoking
Regarding the protective effect of CS on UC, we investigated its impact on the expression of the 65 detoxification genes in the normal colonic mucosa of nine healthy smokers and eight healthy non-smokers. We found that 28 genes were differentially regulated Table 3 ]. It therefore seemed interesting to also assess the effect of CS on UC patients. However, it is usually a clinical challenge to obtain biopsies from UC patients in remission following smoking resumption because of colonoscopy repetition. We had the opportunity to study rare colonic biopsies from five UC patients in clinical, endoscopic, and histological remission following smoking resumption [Supplementary Table 3 ]. The expression of the 65 dysregulated genes was quantified in smoking patients with quiescent UC. Although the small number of patients analysed reduced the statistical power of our analysis, similarities and differences in gene expression levels between the different groups [UC and healthy non-smokers and smokers] were illustrated by principal component analyses [ Figure 2A ]. The subjects were easily classified according to their smoking habits, regardless of their disease status. This result suggests that CS strongly counter-regulates the altered detoxification gene expression in the colon of UC patients grouping together the smoking control and UC groups. Interestingly, the dysregulation of 43 out of the 65 genes observed in UC was inversed by CS, reaching the expression level observed in the control groups [ Figure 2B and Supplementary Table 3 ]. To overcome the limited amount of biopsies from smoking UC patients, non-affected biopsies of non-smoking UC patients were cultured in the presence or absence of cigarette smoke extract [CSE] to test the direct effects induced by CSE on the expression of the 65 dysregulated detoxification genes. CSE inversed the expression level of 47/65 dysregulated genes in non-smoking UC biopsies reaching the expression level observed in the control groups [Supplementary Table 3 ]. These data enhanced the very sharp concordance of cigarette smoke effects in vivo and in vitro on detoxification gene profiles. In order to visualise such an effect, we devised a way of looking at the corresponding pattern of variation between CSE-treated biopsies of non-smoking UC patients and biopsies of smoking UC patients. Since these two groups of data resulted from different normalised conditions [ie, in vitro and in vivo], we used a qualitative approach termed multiple correspondence analysis [MCA] to avoid any suspicion in considering the data as simply qualitative [ Figure 3 and Supplementary Figure 3] . The MCA approach, visualised by means of a biplot with some overlying density curves, shows how highly concentrated zones based on the 65 dysregulated gene expression profiles (ie, no change [nc], and up-or down-regulated) systematically tend to have similar patterns of variations between CSE-treated biopsies of non-smoking UC patients and biopsies of smoking UC patients [ Figure 3 and Supplementary Figure 3] . Upon interpreting these data as categorical, the similarity of the expression profiles labelled as upregulated were found to be the closest between the two groups, followed immediately by those profiles labelled as down-regulated [ Figure 3 ].
Network inference and comparative analysis
We next performed a differential network analysis to investigate the impact of the disease or smoking status on genetic interactions. To this end, our starting assumption was that the observed gene expression pattern was connected through a genetic regulation network [GRN] .
Here, we introduced a novel method on the problem of GRN, based on a dynamic model of genetic interactions and aimed at integrating existing knowledge on genetic interactions by solving a constrained optimisation problem. Thus, we were able to infer a network compatible with the following assumptions and constraints: [i] the observed expression pattern is an equilibrium point for the dynamic model; [ii] some interactions are prohibited due to existing knowledge; and [iii] some interactions are forced to be activating and/or inhibiting. The obtained network, computed on the subset of regulatory genes and for the group of healthy non-smokers, is shown in Figure 4A . This representation highlights the potential role played by FOXO1 in the activation of NR1H3/LXR, and more importantly, the role played by NCOR2 [a repressive co-regulatory factor for multiple transcription factor pathways] in this subnetwork since it is the only gene able to repress other genes.
The resulting inference is a first step to a comparative approach between patients or group of patients, hence focusing on the relative meaning of these networks, as already done in the classical analysis which was more focused on fold changes than on absolute expression levels. To this end, we developed a technique whose aim was to find the minimal number of changes [in terms of sparsity] which should be applied to the control network to obtain a network compatible with the case gene expression profile. In Figure 4B and C, these changes in networks are shown for the comparative analysis between healthy non-smokers and smokers and between non-smoking controls and non-smoking UC patients. For instance, Figure 4B shows how to modify the network of Figure 4A with a minimal effort, to obtain a network compatible with the smoking control group expression patterns. It suggests in particular that the interactions with PPARGC1A are important, in terms of NCOA2 induction and NR1H3/LXR repression. Note that the PPARGC1A gene would not have been studied in a classical gene-based analysis since its fold change was close to 1, showing that the proposed method did not necessarily overlap the classical approach.
Classification and diagnosis
To validate our comparative analysis methodology, we tested its potential application to improve automated diagnosis based on gene expression data [ Figure 5 ]. The diagnosis of UC is challenging and new biomarkers and diagnostic techniques are needed. To this end, we considered the classification problem where a binary variable [healthy subjects or UC patients] must be predicted using only the gene expression data of the 65 genes of interest. The classification performance was evaluated through a standard leave-one-out cross-validation whose score quantifies the proportion p of correct diagnosis. As a benchmark, we applied the Linear Support Vector Machine [L-SVM] classifier on the raw data, giving a classification score p[SVM] = 82%. To exploit our comparative network analysis, a similarity matrix taking the norm of the modification matrices dW between two patients is defined. Based on this similarity matrix, we first performed a multidimensional scaling, projecting data in two dimensions, and then applied the same L-SVM classifier [ Figure 5 ]. The classification score was improved up to p[netSVM] = 89%. For the sake of comparison, if the same method was applied while the correlation of gene expression data is used as an inter-patient similarity measure, the score obtained was much lower (p[corrSVM] = 69%). This analysis showed that the comparative analysis based on the network inference we developed provides a sensitive, yet debatable, characterisation of the differences between two gene expression patterns.
Discussion
An impaired management of xenobiotics in the intestinal mucosa seems to be an important event in IBD initiation and progression. 13, 17, 18, 22, [29] [30] [31] [32] [33] However, the information provided by these studies remains very limited, sometimes conflicting, [34] [35] [36] and relates most often only to one or a small number of genes, without considering that the management of xenobiotics is usually due to the concerted action of many enzymes, transporters and/or factors, and nuclear cofactors in an integrated and interactive network. Moreover, to our knowledge the impact of cigarette smoke, which is known to protect against intestinal inflammation during UC, on the colonic detoxification capacity and coordinated expression of XMEs in humans has never been assessed.
In this study, we focused on the comprehensive expression of 244 XME genes in the non-inflamed mucosa of the ascending colon 12 of UC patients compared with healthy subjects or CD patients. We identified a specific dysregulation of the xenobiotic detoxification system in the non-inflamed colonic mucosa of UC patients, which is not found in healthy controls or patients with colonic CD, providing a clear-cut gene signature for UC. This dysregulation is likely to contribute to the pathophysiology of UC. Interestingly, the expression of several of these dysregulated genes was commonly modified by smoking in the colonic mucosa of healthy controls, supporting the idea that smoking could affect per se the colonic detoxification gene expression. Nuclear receptors and transcription factors which are overarching regulators of the xenobiotic response system, including detoxification enzymes and transporters, were strongly up-regulated in healthy smokers. Moreover, the expression of most genes modulated by tobacco in healthy controls was impaired in UC patients.
One hypothesis could be that CS-induced colonic toxicity could up-regulate detoxification genes. This activation could reach a protective expression level threshold, allowing the colonic mucosa to better support and detoxify endogenous and/or environmental products in patients with susceptibility to develop UC. In this regard, we showed that the expression of the dysregulated detoxification gene set observed in UC patients was similarly reversed in both rare biopsies from UC patients in remission following smoking resumption and CSE-treated biopsies from non-smoking UC patients. Thus, CS could modulate the expression of XME genes in the colonic mucosa and help in normalising this dysregulation in UC, which is essential to the detoxification of xenobiotics.
One weakness of this study is the limited recruitment of patients with UC in remission after smoking resumption. However, the similar effect observed in CSE-treated biopsies of patients with UC helped offset this gap and validated the inducible effect of cigarette smoke on detoxification gene expression. We are also aware that CS could exert its protective effect on colonic mucosa in UC through other mechanisms. Smoking induces alterations to both the innate and the adaptive immune system and is associated with a distinct alteration in the intestinal microbiota both in patients with active CD and in healthy subjects. [37] [38] [39] However, in CSE-treated colonic explants of UC patients, detoxification gene network restoration was observed independently of any microbial/inflammation intervention.
In summary, our findings support that: i] the unaffected mucosa of UC patients exhibited an impaired epithelial detoxification capacity; ii] this signature was specific for UC and distinct from that observed in patients with CD and healthy controls, suggesting different reactivity of colonic mucosa to environmental threats; and iii] CS could selectively change the detoxification gene expression profile in the colonic mucosa of healthy subjects and overcome the impaired detoxification capacity in that of UC patients in connection with its protective effect. However, changes in the global detoxification gene expression profile in smoking patients with CD remains to be determined, to explain the opposite effect of tobacco in IBD.
In order to analyse these experimental data from a network point of view, we introduced a novel approach for the inference and the comparative analysis of genetic regulatory networks, integrating existing biological knowledge into a constrained optimisation problem. These methodological advances have enabled identification of not only new potentially interesting genes but also gene interactions which were not detectable when considering a classical single-gene differential expression analysis. This integrated analysis helped identify two unexpected genes which might play a central role in the overall dysregulation of detoxification genes in UC or in the beneficial effect of CS on UC, despite their limited fold change expression compared with healthy controls. The first gene identified was PPARGC1A [peroxisome proliferator-activated receptor-gamma coactivator 1-alpha], a transcriptional coactivator highly expressed in the intestinal epithelium, able to up-regulate the mitochondrial biogenesis, oxidative phosphorylation, and fatty acid β oxidation. 40 PPARGC1A interacts with several nuclear receptors, including PPARγ which plays key roles in the regulation of inflammation and immune response in UC. [41] [42] [43] [44] Functional, biological, pharmacological, and chemical evidence has shown that PPARγ is an essential receptor mediating the common 5-aminosalicylic acid anti-inflammatory activities in UC patients. 27, 42 The second gene identified by the integrated analysis was NR1H3/LXR which is an important modulator of the inflammatory response in colonic epithelial cells. LXR activation reduces DSS-induced colitis severity 45 and LXR-deficient mice are more susceptible to colitis, 46 suggesting that LXR could reduce the inflammatory responses in IBD. Interestingly, 
